8ix3

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (07:28, 21 November 2024) (edit) (undo)
 
(2 intermediate revisions not shown.)
Line 11: Line 11:
<div style="background-color:#fffaf0;">
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
== Publication Abstract from PubMed ==
-
The continuous emergence of SARS-CoV-2 variants, particularly the newly circulating Omicron XBB subvariants, has led to a significant reduction in the neutralizing potency and breadth of antibodies. In this study, we report a SARS-CoV-2 human neutralizing antibody, 1G11, which potently and broadly neutralizes diverse variants, including Omicron subvariants BA.4/5 and BF.7, but is evaded by the recently emerged BQ.1.1 and XBBs. Cryo-electron microscopy structure analysis of the 1G11 in complex with the BA.4/5 spike trimer reveals that 1G11, a Class 3 nAb, recognizes an epitope similar to those of S309 and LY-CoV1404. Structurally, the mutations K444T and V445P in BQ.1.1 and XBB subvariants are found to disrupt the interface between 1G11 and the spike protein, resulting in antibody evasion. 1G11 is further demonstrated to mediate neutralization through multiple mechanisms, including receptor binding blockage, interspike cross-linking, Fc-mediated ADCC and ADCP. Collectively, these findings provide insights into a better understanding of neutralizing antibody evasion and highlight the potential for broad neutralization by structure-based modification of available antibodies. IMPORTANCE The ongoing COVID-19 pandemic has been characterized by the emergence of new SARS-CoV-2 variants including the highly transmissible Omicron XBB sublineages, which have shown significant resistance to neutralizing antibodies (nAbs). This resistance has led to decreased vaccine effectiveness and therefore result in breakthrough infections and reinfections, which continuously threaten public health. To date, almost all available therapeutic nAbs, including those authorized under Emergency Use Authorization nAbs that were previously clinically useful against early strains, have recently been found to be ineffective against newly emerging variants. In this study, we provide a comprehensive structural basis about how the Class 3 nAbs, including 1G11 in this study and noted LY-CoV1404, are evaded by the newly emerged SARS-CoV-2 variants.
+
The ongoing COVID-19 pandemic has been characterized by the emergence of new SARS-CoV-2 variants including the highly transmissible Omicron XBB sublineages, which have shown significant resistance to neutralizing antibodies (nAbs). This resistance has led to decreased vaccine effectiveness and therefore result in breakthrough infections and reinfections, which continuously threaten public health. To date, almost all available therapeutic nAbs, including those authorized under Emergency Use Authorization nAbs that were previously clinically useful against early strains, have recently been found to be ineffective against newly emerging variants. In this study, we provide a comprehensive structural basis about how the Class 3 nAbs, including 1G11 in this study and noted LY-CoV1404, are evaded by the newly emerged SARS-CoV-2 variants.
-
Structural basis for broad neutralization of human antibody against Omicron sublineages and evasion by XBB variant.,Sun H, Wang Y, Chen X, Jiang Y, Wang S, Huang Y, Liu L, Li Y, Lan M, Guo H, Yuan Q, Zhang Y, Li T, Yu H, Gu Y, Zhang J, Li S, Zheng Z, Zheng Q, Xia N J Virol. 2023 Oct 19:e0113723. doi: 10.1128/jvi.01137-23. PMID:37855619<ref>PMID:37855619</ref>
+
Structural basis for broad neutralization of human antibody against Omicron sublineages and evasion by XBB variant.,Sun H, Wang Y, Chen X, Jiang Y, Wang S, Huang Y, Liu L, Li Y, Lan M, Guo H, Yuan Q, Zhang Y, Li T, Yu H, Gu Y, Zhang J, Li S, Zheng Z, Zheng Q, Xia N J Virol. 2023 Nov 30;97(11):e0113723. doi: 10.1128/jvi.01137-23. Epub 2023 Oct , 19. PMID:37855619<ref>PMID:37855619</ref>
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
</div>
<div class="pdbe-citations 8ix3" style="background-color:#fffaf0;"></div>
<div class="pdbe-citations 8ix3" style="background-color:#fffaf0;"></div>
 +
 +
==See Also==
 +
*[[Spike protein 3D structures|Spike protein 3D structures]]
== References ==
== References ==
<references/>
<references/>

Current revision

Cryo-EM structure of SARS-CoV-2 BA.4/5 spike protein in complex with 1G11 (local refinement)

PDB ID 8ix3

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/8ix3"
Personal tools